NASDAQ:GMTX Gemini Therapeutics (GMTX) Stock Price, News & Analysis $60.48 -1.58 (-2.55%) As of 10/12/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsSEC Filings About Gemini Therapeutics Stock (NASDAQ:GMTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gemini Therapeutics alerts:Sign Up Key Stats Today's Range$60.36▼$62.7650-Day Range$60.48▼$82.6752-Week Range$1.16▼$14.10Volume657,218 shsAverage Volume189,291 shsMarket Capitalization$2.62 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Gemini Therapeutics, Inc. was a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. Its research centered on the complement system, an area of the immune system implicated in several ophthalmic and inflammatory conditions. The company’s lead product candidate was GEM103, a recombinant form of complement factor H being investigated as a potential treatment for geographic atrophy, an advanced form of dry age-related macular degeneration. Gemini evaluated GEM103 in clinical studies and explored its use in patients with complement-related genetic risk factors. Gemini later discontinued development of GEM103 and pursued strategic alternatives. In 2023, the company completed a business combination with Disc Medicine, a biotechnology company developing treatments for hematologic diseases. The combined company operates as Disc Medicine, while Gemini Therapeutics is no longer an independent operating company.AI Generated. May Contain Errors. Read More Receive GMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMTX Stock News HeadlinesGemini Therapeutics (NASDAQ:GMTX) Stock Jumps 1.4% - Time to Buy?October 6, 2026 | americanbankingnews.comFDA reversals leave investors worrying about the fates of other experimental drugsMarch 6, 2026 | cnbc.comI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 14 at 1:00 AM | Weiss Ratings (Ad)What Is Gemini? Everything You Should Know About Google's AI ToolOctober 17, 2024 | cnet.comGemini Review 2024: Is This Crypto Exchange a Gem for Your Investments?July 22, 2024 | businessinsider.comGoogle's public release of Gemini 1.5 should build trust, Deutsche Bank saysApril 17, 2024 | seekingalpha.com(SPAC) Special Purpose Acquisition Investigation: PRDS, GMTX, SNTI, TNGX - Contact Shareholder Rights Law Firm Johnson FistelJune 24, 2023 | benzinga.comBronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Gemini Therapeutics, Inc. (GMTX) InvestigationJune 1, 2023 | barrons.comSee More Headlines GMTX Stock Analysis - Frequently Asked Questions How have GMTX shares performed this year? Gemini Therapeutics' stock was trading at $79.41 on January 1st, 2026. Since then, GMTX stock has decreased by 23.8% and is now trading at $60.48. How were Gemini Therapeutics' earnings last quarter? Gemini Therapeutics, Inc. (NASDAQ:GMTX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.04. How do I buy shares of Gemini Therapeutics? Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gemini Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gemini Therapeutics investors own include Advanced Micro Devices (AMD), FuelCell Energy (FCEL), Lucid Group (LCID), Micron Technology (MU), Ocugen (OCGN), Plug Power (PLUG) and Alibaba Group (BABA). Company Calendar Last Earnings11/15/2021Today10/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GMTX CIK1816736 Webwww.geminitherapeutics.com Phone415-877-4887FaxN/AEmployees30Year Founded2015Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$71.87 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.78% Return on Assets-35.88% Debt Debt-to-Equity RatioN/A Current Ratio71.49 Quick Ratio71.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / Book20.93Miscellaneous Outstanding Shares43,328,000Free Float37,739,000Market Cap$2.62 billion OptionableNot Optionable Beta-0.12 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:GMTX) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Play Kevin O'Leary Is BackingKevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...The Tomorrow Investor | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredAI Microcap Teams With Gentex on Next-Gen Military HelmetsMorgan Stanley projects the humanoid robotics market could reach $5 trillion by 2050, with more than 1 billion...Capital Trends | SponsoredMy next big call (under $1)The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a...Crypto 101 Media | SponsoredElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
